New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 25, 2014
04:55 EDTCYH, CYH, BAX, BAX, CAH, CAH, KND, KND, CRY, CRY, MDCO, MDCO, SRDX, SRDX, XOMA, XOMA, PRGO, PRGO, IDRA, IDRA, EBS, EBS, CVS, CVSRBC Capital to hold a conference
Healthcare Conference is being held in New York on February 25-26.
News For CYH;EBS;IDRA;PRGO;XOMA;SRDX;MDCO;CRY;KND;CAH;BAX;CVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
April 15, 2015
17:49 EDTMDCOThe Medicines Co. up 7% after FDA panel backs approval of cangrelor
Subscribe for More Information
17:18 EDTMDCOThe Medicines Co. confirms FDA Advisory Committee backs approval of cangrelor
Subscribe for More Information
15:37 EDTMDCOFDA panel votes in favor of approval for cangrelor
Subscribe for More Information
10:36 EDTCAHBofA/Merrill U.S. credit analysts hold an analyst/industry conference call
Subscribe for More Information
09:54 EDTKNDWells positive on HealthSouth, Kindred after ''doc fix'' bill
Subscribe for More Information
09:02 EDTPRGORBC sees Akorn as possible play on Perrigo takeover interest
Subscribe for More Information
08:40 EDTCYHHospital stocks rise in pre-market after HCA boosts 2015 guidance
Subscribe for More Information
08:13 EDTBAXCoherus, Baxter announce amendment to etanercept biosimilar agreement
Coherus BioSciences (CHRS) and Baxter International (BAX) announced that they have amended certain financial terms of their collaboration agreement established in August 2013 regarding the development and commercialization of CHS-0214, an etanercept biosimilar product candidate, for Europe, Canada, Brazil, and certain other markets. Under the terms of the amended agreement, certain existing milestones and funding obligations have been revised, and the collaboration has been expanded to include select pre-commercialization activities. In aggregate, the revised milestone payments may exceed the previous Baxter funding obligations by approximately $12M. Additionally, Baxter has agreed to purchase Coherus common stock in a private placement transaction. All other contractual provisions remain materially unchanged.
07:57 EDTMDCOThe FDA Cardiovascular & Renal Drugs Advisory Committee to hold a meeting
The Committee discusses The Medicines Company's New Drug Application (NDA) 204958 Cangrelor injection for proposed indication of reduction of thrombotic cardiovascular events at a meeting being held at FDA Silver Spring, Maryland offices on April 15 at 8 am. Webcast Link
07:01 EDTMDCOThe Medicines Co. stock trading halted today
Subscribe for More Information
06:09 EDTPRGOStocks with implied volatility below IV index mean; FXE PRGO
Subscribe for More Information
April 14, 2015
10:50 EDTPRGOOptions with increasing implied volatility
Subscribe for More Information
07:38 EDTBAXBaxter removed from the short-term buy list at Deutsche Bank
Subscribe for More Information
07:05 EDTIDRANeedham to hold a conference
Subscribe for More Information
April 13, 2015
14:07 EDTCAHEarnings Watch: Johnson & Johnson shares down slightly since last earnings
Subscribe for More Information
11:13 EDTMDCOFDA panel briefing docs look positive for Medicines Co., says Leerink
Subscribe for More Information
10:48 EDTPRGOOptions with increasing implied volatility
Options with increasing implied volatility: CLDN WETF EWH FOSL FXI TLM PRGO ATHN SYMC MAC
10:15 EDTMDCOHigh option volume stocks
Subscribe for More Information
07:56 EDTPRGOMylan, Teva, Perrigo price targets raised at JPMorgan
Subscribe for More Information
06:49 EDTPRGOMylan notifies Perrigo of HSR filing regarding proposed acquisition
Mylan N.V. (MYL) announced that it has provided Perrigo (PRGO) with notice of its filing of the premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with the U.S. Federal Trade Commission and the U.S. Department of Justice Antitrust Division regarding its proposed acquisition of Perrigo, as required by the HSR Act. Mylan proposed to acquire Perrigo for $205 per share in a cash-and-stock transaction on April 6.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use